Tag: JNJ
-

4 Income ETFs That Could Help Investors Navigate Market Volatility
Consider these four income ETFs to help diversify and safeguard your portfolio from market volatility.
-

3 High-Yield Dividend ETFs to Protect Your Portfolio
In times of chaos, dividend ETFs can offer investors a compelling mix of stability, passive income, and long-term growth.
-

Johnson & Johnson Is Proving To Be Less Dependent On Patent Cliffs
Johnson & Johnson beat earnings and raised guidance, showing its diversified business is becoming less dependent on blockbuster drug patents.
-

Dogs of the Dow 2026: One of the Best Investment Strategies
The Dogs of the Dow are off to another strong year. See why this time-tested dividend strategy continues to reward long-term investors.
-

3 Top Dividend ETFs to Buy for Income, Stability, and Long-Term Growth
Looking for income and stability? These three dividend ETFs offer reliable yields, quality holdings, and long-term growth potential.
-

AbbVie vs. JNJ: Which Biopharma Stock Wins in 2026?
Biopharma stocks may benefit from sector rotation. AbbVie and Johnson & Johnson deserve a close look, but they are not the same trade.
-

3 High-Yield Dividend ETFs to Protect Your Portfolio From Market Volatility
In times of market volatility, investors can strengthen their portfolios by incorporating diversified, income-producing dividend ETFs.
-

3 High-Yield Dividend Stocks to Buy and Hold Forever
High-yield dividend stocks can help investors generate passive income while adding stability during volatile markets.
-

Protect Your Portfolio with 3 High-Yielding Dividend ETFs
In uncertain markets, dividend ETFs —especially those emphasizing companies with long histories of growing payouts—can help anchor your portfolio.
-

3 of the Best High-Yielding ETFs to Own Right Now
High-yielding ETFs can be powerful tools for building a steady stream of passive income, particularly for retirees or those nearing retirement